GlassScriptPhysician profile
Greta Heckmann
NPI 1427658368
$28,397.58
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,436 · 2022: $1,823 · 2023: $2,556 · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $8,191 · Travel and Lodging: $3,578 · Consulting Fee: $330 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,881.00 |
| Food and Beverage | $8,190.65 |
| Travel and Lodging | $3,578.29 |
| Consulting Fee | $330.00 |
| Education | $158.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $19,484.91 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $2,232.04 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,644.35 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,270.34 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,061.23 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $871.24 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $507.86 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $470.29 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $275.41 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $173.51 | 2023-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $125.76 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $88.68 | 2023-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $39.68 | 2025 | Loreev Xr |
| Harmony Biosciences LLC | $31.64 | 2025 | |
| Indivior INC. | $29.30 | 2023 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $23.38 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $19.85 | 2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $17.83 | 2025 | Cobenfy |
| Tris Pharma INC | $16.92 | 2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $13.36 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greta Heckmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.